DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for anterior segment dysgenesis 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAnterior segment dysgenesis 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for anterior segment dysgenesis 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Anterior segment dysgenesis 4 is not a distinct clinical entity in the available abstracts. The 2011 review of 220 eyes from 139 patients at a single Japanese centre found that the most common clinical diagnosis among anterior segment dysgenesis cases was Peters anomaly (72.7%), followed by anterior staphyloma (11.4%), Rieger anomaly (7.7%), and sclerocornea (6.4%). Among 61 patients whose visual acuity was measured, 43.2% had best-corrected visual acuity in the better eye between 20/60 and 20/1000 (low vision), and 24.3% had acuity less than 20/1000 (legally blind). Fundus disorders were found in 14.6% of examined eyes, systemic abnormalities in 25.2% of patients, and a family history in only 3.6%. Of the 109 patients with Peters anomaly, 46.8% had bilateral disease, 27.5% had a normal fellow eye, and 25.7% had other abnormal findings in the fellow eye.
A 1997 case series of four girls with mosaic Turner syndrome reported anterior chamber abnormalities in all four, with three presenting with congenital glaucoma. Karyotypes included 45,X/46,X,idic(Y) in two patients, 45,X/47,XXX in one, and 45,X/46,X,r(X) in the remaining child who had a Rieger malformation of the iris. The authors noted that Turner syndrome mosaicism involving two abnormal cell lines appeared associated with anterior segment dysgenesis, and they speculated that the presence of two or more genetically different cell lines might adversely affect anterior segment development.
Two review papers from 2004 and 2018 summarise developmental mechanisms. The 2004 review describes anterior segment development as involving inductive interactions between neural ectoderm, surface ectoderm, and periocular mesenchyme, and lists genes associated with abnormal development and elevated intraocular pressure in mouse models: Bmp4, Cyp1b1, Foxc1, Foxc2, Pitx2, Lmx1b, and Tyr. The 2018 review states that periocular mesenchyme is comprised of neural crest-derived mesenchymal progenitor cells that give rise to the cornea and trabecular meshwork, and identifies PITX2, FOXC1, and Tfap2b as genes involved in migration and specification of this tissue. Neither review provides patient outcome data or tests a specific intervention.
What is missing is any prospective trial testing a treatment for anterior segment dysgenesis 4, any molecular confirmation that the cases described share a single genetic aetiology, and any stratification of patients by genotype or developmental stage. The existing literature is limited to retrospective case series and developmental biology reviews; no funding for a targeted therapy trial or a registry that links genotype to visual outcome is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The International Journal of Developmental Biology · 2004 · 196 citations · open access
Anterior segment development relevant to glaucoma
AbstractDevelopment of the ocular anterior segment involves a series of inductive interactions between neural ectoderm, surface ectoderm and periocular mesenchyme. The timing of these events is well established but less is known about the molecular mechanisms involved. Various genes that participate in these processes have been identified. As the roles of more genes are determined, developmental pathways and networks will emerge. Here, we focus on recent advances made using mouse models. We summarize key morphological events in formation of anterior chamber structures, including the aqueous humor drainage structures that are involved in intraocular pressure (IOP) regulation and glaucoma. We discuss the developmental roles of genes that associate with abnormal anterior segment development and elevated IOP or glaucoma (including Bmp4, Cyp1b1, Foxc1, Foxc2, Pitx2, Lmx1b and Tyr ) and how some of these genes may fit into developmental networks.
Clinical Features of Anterior Segment Dysgenesis Associated With Congenital Corneal Opacities
AbstractPURPOSE: Anterior segment dysgenesis is one of the main causes of congenital corneal opacities. In this study, we investigated the clinical features and visual outcomes of patients with anterior segment dysgenesis in a large number of cases. METHODS: The medical records of patients with congenital corneal opacities in relation to anterior segment dysgenesis seen in the National Center for Child Health and Development, Japan, between April 2002 and October 2009, were retrospectively studied. RESULTS: Records of 220 eyes of 139 patients were reviewed. Mean follow-up period was 5 years. Clinical diagnoses were Peters anomaly (72.7%), anterior staphyloma (11.4%), Rieger anomaly (7.7%), sclerocornea (6.4%), and others (1.8%). Visual acuity was measured in 61 patients. The best-corrected visual acuity in the better eye of bilaterally involved patients was 20/60 to 20/1000 (low vision according to the International Classification of Diseases, Ninth Revision, Clinical Modification) in 43.2% and less than 20/1000 (legally blind) in 24.3%. Fundus examination was performed in 82 eyes, and disorders were seen in 12 (12 of 82; 14.6%). Systemic abnormalities were present in 35 patients (35 of 139; 25.2%); a family history was present in 5 patients (5 of 139; 3.6%). Of the 160 eyes of 109 patients with Peters anomaly, 51 patients (51 of 109; 46.8%) had bilateral Peters anomaly, 30 (30 of 109; 27.5%) had fellow eyes that were normal, and 28 (28 of 109, 25.7%) showed other abnormal ocular findings in the fellow eye. CONCLUSIONS: Anterior segment dysgenesis shows diverse clinical features, various severities of corneal opacities, and visual outcomes. Further understanding of the disease as an abnormality during embryogenesis and neural crest cell differentiations may be required.
British Journal of Ophthalmology · 1997 · 33 citations · open access
Anterior segment dysgenesis in mosaic Turner syndrome
AbstractAIMS/BACKGROUND: Females with Turner syndrome commonly exhibit ophthalmological abnormalities, although there is little information in the literature documenting findings specific to Turner syndrome mosaics. Ophthalmic findings are described in four patients with mosaic Turner syndrome. All had anterior chamber abnormalities and all four had karyotypic abnormalities with a 45, X cell line. The possible relation between the karyotypic and the phenotypic findings in these patients is discussed. METHODS: Four girls with mosaic Turner syndrome underwent a full ophthalmological assessment, including examination under anaesthesia where indicated. RESULTS: Three of the four patients presented with congenital glaucoma. Two had the karyotype 45, X/46, X, idic(Y) and one a 45, X/47, XXX karyotype. The remaining child had a Rieger malformation of the iris and the karyotype 45, X/46, X, r(X). CONCLUSIONS: These findings suggest that Turner syndrome mosaicism (where there are two abnormal cell lines) is associated with anterior segment dysgenesis. The findings in these four patients are compared with those seen in other mosaic phenotypes and it is postulated that the presence of two or more genetically different cell lines may have an adverse effect on anterior segment development.
Relationship Between Neural Crest Cell Specification and Anterior Segment Dysgenesis
AbstractDevelopment of the anterior segment of the eye is closely associated with neural crest cell migration and specification. Its development is complex as it requires the functioning of a combination of local factors, receptors, inductors, and signalling between tissues such as the optic cup and periocular mesenchyme (POM). POM is comprised of neural crest-derived mesenchymal progenitor cells that give rise to numerous important anterior segment structures such as the cornea, and trabecular meshwork. Several genes involved in the migration and specification of the POM have been identified, including PITX2, FOXC1, and Tfap2b. The author, with the help of Judith West-Mays and Vanessa Martino, has conducted an extensive literature search on recently published articles surrounding anterior segment dysgenesis and its associated genes and transcription factors in order to construct this review paper.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
